Literature DB >> 31285528

Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.

Ken-Ichi Yoshida1, Yoshiko Nakano2, Mai Honda-Kitahara2, Susumu Wakai1, Toru Motoi3, Koichi Ogura4, Naoki Sano3, Tatsuhiro Shibata4, Tomotake Okuma5, Shintaro Iwata6,7, Akira Kawai6,7, Koichi Ichimura2,7, Akihiko Yoshida8,9.   

Abstract

Giant cell tumor of bone typically involves the epiphysis of the long bones of skeletally mature patients. It is genetically characterized by highly recurrent and specific mutations of the H3F3A gene, which encodes histone H3.3. The most common mutation H3F3A G34W can readily be detected by a recently developed mutation-specific antibody. Giant cell tumor of bone rarely transforms to a sarcoma (malignant giant cell tumor of bone), which has not been genetically characterized in detail. We studied seven clinicopathologically defined malignant giant cell tumors, as well as two H3F3A-mutant bone sarcomas without giant cell tumor histology using a combination of clinicopathological, immunohistochemical, and molecular methods (Sanger sequencing + pyrosequencing or next generation sequencing). The cases included five men and four women, with a median age at initial diagnosis of 27 years. The two H3F3A G34W-positive sarcomas without giant cell tumor histology involved the subarticular epiphyseal sites, suggesting relatedness with giant cell tumor of bone. In two of the seven clinicopathologically defined malignant giant cell tumor cases, the sarcoma tissue showed the H3F3A G34W mutation. However, in the remaining five cases, in contrast to their associated H3F3A G34W-mutant giant cell tumor, the sarcoma lacked the H3F3A G34W mutation, either entirely or sub-clonally in the samples tested. This discordant mutation status was confirmed in all instances by immunohistochemistry and sequencing. A FISH analysis suggested that the absence of the H3F3A G34W mutation may be related to deletion of the H3F3A gene. Therefore, we have demonstrated that H3F3A G34W mutation, a critical driver in giant cell tumor, is absent in a subset of malignant giant cell tumor of bone. This novel recurrent phenomenon has potential biological and diagnostic implications, and further study is required to better characterize this progression pathway and understand its mechanism.

Entities:  

Year:  2019        PMID: 31285528     DOI: 10.1038/s41379-019-0318-5

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  11 in total

Review 1.  Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.

Authors:  Hidetaka Yamamoto; Shin Ishihara; Yu Toda; Yoshinao Oda
Journal:  Med Mol Morphol       Date:  2019-11-20       Impact factor: 2.309

2.  Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.

Authors:  Lorena Ligammari; Hang-Mao Lee; Helen J Knowles; Lucia Cottone; Stephen Henderson; Sara Bianco; Christopher Davies; Sandra Strauss; Fernanda Amary; Ana Paula Leite; Roberto Tirabosco; Kristian Haendler; Joachim L Schultze; Javier Herrero; Paul O'Donnell; Agamemnon E Grigoriadis; Paolo Salomoni; Adrienne M Flanagan
Journal:  Cell Death Differ       Date:  2022-08-03       Impact factor: 12.067

Review 3.  Secondary Malignancy in Giant Cell Tumor: A Single-Center Study.

Authors:  Min Wook Joo; Yong-Suk Lee; Hong Sik Park; Yang-Guk Chung; Chiyoung Yoon
Journal:  Curr Oncol       Date:  2022-06-02       Impact factor: 3.109

4.  Malignancy in giant cell tumor of bone in the extremities.

Authors:  Weifeng Liu; Chung Ming Chan; Lihua Gong; Marilyn M Bui; Gang Han; G Douglas Letson; Yongkun Yang; Xiaohui Niu
Journal:  J Bone Oncol       Date:  2020-11-05       Impact factor: 4.072

Review 5.  Complex Elucidation of Cells-of-Origin in Pediatric Soft Tissue Sarcoma: From Concepts to Real Life, Hide-and-Seek through Epigenetic and Transcriptional Reprogramming.

Authors:  Clara Savary; Cécile Picard; Nadège Corradini; Marie Castets
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

Review 6.  Soft Tissue Special Issue: Giant Cell-Rich Lesions of the Head and Neck Region.

Authors:  Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Head Neck Pathol       Date:  2020-01-16

Review 7.  The epigenomics of sarcoma.

Authors:  Benjamin A Nacev; Kevin B Jones; Andrew M Intlekofer; Jamie S E Yu; C David Allis; William D Tap; Marc Ladanyi; Torsten O Nielsen
Journal:  Nat Rev Cancer       Date:  2020-08-11       Impact factor: 69.800

8.  Diagnostic Utility of Genetic and Immunohistochemical H3-3A Mutation Analysis in Giant Cell Tumour of Bone.

Authors:  Michał Wągrodzki; Andrzej Tysarowski; Katarzyna Seliga; Aneta Wojnowska; Maria Stepaniuk; Patrycja Castañeda Wysocka; Donata Makuła; Andrzej Pieńkowski; Bartłomiej Szostakowski; Renata Zub; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2022-01-16       Impact factor: 5.923

Review 9.  State of the Art and New Concepts in Giant Cell Tumor of Bone: Imaging Features and Tumor Characteristics.

Authors:  Anna Parmeggiani; Marco Miceli; Costantino Errani; Giancarlo Facchini
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

10.  Drivers underpinning the malignant transformation of giant cell tumour of bone.

Authors:  Sam Behjati; Adrienne M Flanagan; Matthew W Fittall; Iben Lyskjaer; Peter Ellery; Patrick Lombard; Jannat Ijaz; Anna-Christina Strobl; Dahmane Oukrif; Maxime Tarabichi; Martin Sill; Christian Koelsche; Gunhild Mechtersheimer; Jonas Demeulemeester; Roberto Tirabosco; Fernanda Amary; Peter J Campbell; Stefan M Pfister; David Tw Jones; Nischalan Pillay; Peter Van Loo
Journal:  J Pathol       Date:  2020-10-06       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.